Published in J Thromb Haemost on November 22, 2007
Double-blindness protects scientific validity. J Thromb Haemost (2007) 1.77
Factors influencing recruitment to research: qualitative study of the experiences and perceptions of research teams. BMC Med Res Methodol (2014) 1.02
Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium. Respir Res (2012) 0.87
Open-label trials and drug registration: a European regulator's view. J Thromb Haemost (2007) 0.79
Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med (2001) 5.67
Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol (2000) 3.36
Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med (1997) 3.08
Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest (2001) 2.72
Left atrial diameter in nonvalvular atrial fibrillation: An echocardiographic study. Stroke Prevention in Atrial Fibrillation Investigators. Am Heart J (1999) 2.68
Is it useful to also image the asymptomatic leg in patients with suspected deep vein thrombosis? J Thromb Haemost (2015) 2.62
Detection of Chlamydia trachomatis infection in urine samples from men and women by ligase chain reaction. J Clin Microbiol (1995) 2.50
Non-invasive diagnosis of venous thromboembolism in outpatients. Lancet (1999) 2.46
Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS (2001) 2.41
Postoperative pulmonary embolism after hospital discharge. An underestimated risk. Arch Surg (1992) 2.33
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost (2013) 2.24
Assessing clinical probability of pulmonary embolism in the emergency ward: a simple score. Arch Intern Med (2001) 2.23
Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. Arch Intern Med (2000) 2.15
Performance of helical computed tomography in unselected outpatients with suspected pulmonary embolism. Ann Intern Med (2001) 2.11
Risk factors for human herpesvirus 8 seropositivity and seroconversion in a cohort of homosexual men. Am J Epidemiol (2000) 2.05
Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association. Circulation (2001) 2.01
Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol (1998) 1.95
[Hepatitis C in the Netherlands: sparse data on the current prevalence and the necessity for epidemiological studies and innovative methods for detecting infected individuals]. Ned Tijdschr Geneeskd (2007) 1.87
Regional distribution and incidence of human papillomavirus infections among heterosexual men and women with multiple sexual partners: a prospective study. Genitourin Med (1994) 1.73
Diagnosing deep vein thrombosis: the case for compression ultrasonography limited to the proximal veins. J Thromb Haemost (2004) 1.71
Antibiotic treatment is associated with reduced risk of a subsequent exacerbation in obstructive lung disease: an historical population based cohort study. Thorax (2008) 1.68
Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users compared with homosexual men. AIDS (1995) 1.63
D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost (2006) 1.62
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost (2008) 1.55
Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol (1992) 1.55
Resistance to activated protein C in an unselected population of patients with pulmonary embolism. Lancet (1996) 1.54
Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. J Bone Joint Surg Br (1999) 1.52
Value of brush cytology for dominant strictures in primary sclerosing cholangitis. Endoscopy (1999) 1.51
One-year results of a smoking-cessation programme. Schweiz Med Wochenschr (1999) 1.50
Increase in extracellular glutamate caused by reduced cerebral perfusion pressure and seizures after human traumatic brain injury: a microdialysis study. J Neurosurg (1998) 1.49
Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol (2000) 1.49
Atrial fibrillation and stroke. Revisiting the dilemmas. Stroke (1994) 1.49
Pathophysiology of Raynaud's disease. Arch Intern Med (1979) 1.47
Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER). Ann Oncol (2009) 1.47
Atrial fibrillation--risk marker for stroke. N Engl J Med (1990) 1.46
Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost (2000) 1.45
Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism. J Thromb Haemost (2013) 1.45
Outpatient percutaneous transluminal angioplasty for peripheral arterial disease. Eur J Med (1992) 1.42
Characterization of RNA-mediated resistance to tomato spotted wilt virus in transgenic tobacco plants. Biotechnology (N Y) (1992) 1.42
Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med (1999) 1.41
Relationship between peripheral vascular disease and high plantar pressures in diabetic neuro-ischaemic patients. Diabetes Metab (2003) 1.41
Videodensitometric quantitative angiography after coronary balloon angioplasty, compared to edge-detection quantitative angiography and intracoronary ultrasound imaging. Eur Heart J (2000) 1.39
Progressive biparietal atrophy: an atypical presentation of Alzheimer's disease. J Neurol Neurosurg Psychiatry (1996) 1.39
Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure. Circulation (1981) 1.35
Opting out increases HIV testing in a large sexually transmitted infections outpatient clinic. Sex Transm Infect (2008) 1.34
Effects of age on the performance of common diagnostic tests for pulmonary embolism. Am J Med (2000) 1.33
Migrants travelling to their country of origin: a bridge population for HIV transmission? Sex Transm Infect (2008) 1.31
Clinical and echocardiographic features of intermittent atrial fibrillation that predict recurrent atrial fibrillation. Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Am J Cardiol (1995) 1.31
D-Dimer for venous thromboembolism diagnosis: 20 years later. J Thromb Haemost (2008) 1.27
Atrial fibrillation and stroke : concepts and controversies. Stroke (2001) 1.27
Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J Am Soc Echocardiogr (1999) 1.22
Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2. J Viral Hepat (2015) 1.22
Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation (1988) 1.22
Comparison of four strategies for diagnosing deep vein thrombosis: a cost-effectiveness analysis. Am J Med (2001) 1.22
International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost (2013) 1.21
An Alu-mediated 7.1 kb deletion of BRCA1 exons 8 and 9 in breast and ovarian cancer families that results in alternative splicing of exon 10. Genes Chromosomes Cancer (2000) 1.21
Diagnosing pulmonary embolism: running after the decreasing prevalence of cases among suspected patients. J Thromb Haemost (2004) 1.21
Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of captopril with observations on sustained oral therapy. Am Heart J (1981) 1.19
D-dimer testing for suspected pulmonary embolism in outpatients. Am J Respir Crit Care Med (1997) 1.14
Characterization of the pea ENOD12B gene and expression analyses of the two ENOD12 genes in nodule, stem and flower tissue. Mol Gen Genet (1991) 1.13
Influence of age on the cost-effectiveness of diagnostic strategies for suspected pulmonary embolism. J Thromb Haemost (2007) 1.12
Pregnancies before and after HIV diagnosis in a european cohort of HIV-infected women. European Study on the Natural History of HIV Infection in Women. AIDS (2000) 1.12
Characterization of endothelial-like cells derived from human mesenchymal stem cells. J Thromb Haemost (2007) 1.09
Low molecular weight heparin: a critical analysis of clinical trials. Pharmacol Rev (1994) 1.08
Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol (2001) 1.06
A simple G-computation algorithm to quantify the causal effect of a secondary illness on the progression of a chronic disease. Stat Med (2009) 1.06
Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials. J Thromb Haemost (2013) 1.05
Diagnosis of pulmonary embolism by a decision analysis-based strategy including clinical probability, D-dimer levels, and ultrasonography: a management study. Arch Intern Med (1996) 1.05
Using clinical evaluation and lung scan to rule out suspected pulmonary embolism: Is it a valid option in patients with normal results of lower-limb venous compression ultrasonography? Arch Intern Med (2000) 1.03
The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2. J Viral Hepat (2015) 1.02
Clinical prediction rules for pulmonary embolism: a systematic review and meta-analysis. J Thromb Haemost (2010) 1.02
Severe iatrogenic ergotism: incidence and clinical importance. Vasa (1991) 1.02
Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. Am J Med (2000) 1.02
Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood (2000) 1.02
Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology (2000) 1.00
Performances of the VIDAS D-dimer new assay for the exclusion of venous thromboembolism. Thromb Haemost (2001) 0.98
Contribution of noninvasive evaluation to the diagnosis of pulmonary embolism in hospitalized patients. Eur Respir J (1999) 0.97
D-dimer plasma concentration in various clinical conditions: implication for the use of this test in the diagnostic approach of venous thromboembolism. Thromb Res (1993) 0.97
Using phylogenetic analysis to trace HIV-1 migration among western European injecting drug users seroconverting from 1984 to 1997. AIDS (2001) 0.97
Should the D-dimer cut-off value be increased in elderly patients suspected of pulmonary embolism? Thromb Haemost (2001) 0.97
Mitral regurgitation associated with reduced thromboembolic events in high-risk patients with nonrheumatic atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Am J Cardiol (1993) 0.97
Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J Thromb Haemost (2010) 0.96
Long-term results of the Simon nitinol inferior vena cava filter. Eur Radiol (1998) 0.96
Left ventricular thrombi and cerebral embolism. N Engl J Med (1989) 0.95
The prevalence and one-year outcome of limb arterial obstructive disease in a nursing home population. J Am Geriatr Soc (1988) 0.95
Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol (2009) 0.95
Cardiac biomarkers for risk stratification in non-massive pulmonary embolism: a multicenter prospective study. J Thromb Haemost (2009) 0.94
Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. J Pharmacol Exp Ther (1985) 0.94
Disrupted compaction of CNS myelin in an OSP/Claudin-11 and PLP/DM20 double knockout mouse. Mol Cell Neurosci (2005) 0.94
Determinants of response to first HAART regimen in antiretroviral-naïve patients with an estimated time since HIV seroconversion. HIV Med (2006) 0.94
Cost-effective diagnosis of deep vein thrombosis and pulmonary embolism. Thromb Haemost (2001) 0.93
Ongoing transmission of a single hepatitis B virus strain among men having sex with men in Amsterdam. J Viral Hepat (2009) 0.93
D-dimer testing and venous thromboembolism: four view points. J Thromb Haemost (2005) 0.93
Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. Circulation (1986) 0.93
Outpatient treatment of pulmonary embolism is feasible and safe in a substantial proportion of patients. J Thromb Haemost (2003) 0.92
Left ventricular thrombus and stroke after myocardial infarction: toward prevention or perplexity? J Am Coll Cardiol (1989) 0.92